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Background: It has been demonstrated that eIF3f expression is significantly decreased in many human cancers, a
fact which plays an important role in human cancer. However, the expression of eIF3f in gastric cancer (GC) is not
well understood to date. Therefore, the aim of this study is to detect the expression of eIF3f in GC.
Methods: The expression of eIF3f was examined by immunohistochemistry in tissues with stage I to III GC and
adjacent non-cancerous tissues (ANCT) of 195 gastrectomy specimens; clinicopathological results, including survival,
were analyzed.
Results: The positive expression rate of eIF3f was significantly higher in ANCT tissues than in GC. eIF3f levels were
correlated with more advanced tumor stages and likelihood of recurrence (all P <0.05). The Kaplan-Meier survival
curves indicated that decreased expression of eIF3f could serve as a prognosis marker for poor outcome of GC
patients (P = 0.04).
Conclusions: eIF3f may play an important role in recurrence, thus representing a promising predictive marker for
the prognosis of GC.
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From a global perspective, gastric cancer (GC) is the
fourth most common malignant tumor and the second
cause of cancer-related death, accounting for an esti-
mated 989,600 new cases and 738,000 deaths in 2008
[1-3]. In the past several decades, intensive efforts have
been made to identify tools to improve prognostication
of gastric cancer; miR-21, miRNA-106a, and miR-143, as
well as miR-203 are considered to be promising novel
biomarkers for GC [4]. However, except for the cancer
staging, upon which adjuvant treatment depends, defin-
ite predictive factors for the prognosis of GC are rela-
tively scarce [5-8]. Thus, finding new prognostic tools,
such as biomarkers, for the accurate diagnosis of GC is
of vital importance to improve the therapeutic effect and
prolong the survival of patients.* Correspondence: chuanjinsun@126.com
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reproduction in any medium, provided the orThe eukaryotic initiation factor 3f (eIF3f ) is the p47
subunit of the multi-subunit eIF3 complex and plays an
important role in translation initiation [9-11]. Although
the role of eIF3f in the eIF3 complex has not been
defined [12-14], shut-off experiments in Schizosaccharo-
myces pombe showed that in a long-term period, eIF3f
was essential for viability [15]. The translation system
indicated that, in mammalian cells, eIF3f was a negative
regulator of translation, which played an important role
in human cancer [12,16]. A study by Marchione et al.
showed that the f subunit of eIF3 represented a promis-
ing candidate molecule to use for bio-therapeutic appli-
cations [17]. Previous studies have identified eIF3f as a
protein involved in apoptotic signaling as a negative
regulator of translation and have also demonstrated that
eIF3f expression significantly decreased in many human
cancers, and thus played an important role in human
cancer [11,16,18,19]. Shi et al. reported that eIF3f was
downregulated in several human tumors, and that its
overexpression inhibited cell proliferation in melanomahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Higareda-Mendoza and Pardo-Galván also showed that
eIF3f was essential for A549 cell proliferation and its
absence induced the cell to enter apoptosis [20].
Together, these previous findings suggest that eIF3f
may be involved in the regulation of cell growth and
proliferation and contributes to tumorigenesis; however,
its role in GC remains unclear. Thus, in order to shed
light into the expression of eIF3f in GC, we correlated
eIF3f expression results with the clinicopathologic char-
acteristics and prognosis of GC patients. We conducted
experiments to characterize the localization of eIF3f by
immunohistochemistry, aiming to find a new prognostic
marker for GC and new diagnosis and treatment strategies.
Methods
Patient samples
A review of surgical specimens at the The Second
Hospital of Shandong University between November
2007 and March 2009 yielded 195 cases of GC patients
who had undergone curative surgery. The mean age of the
patients was 62 years (range, 31–90 years). The median
follow-up period was 38 months (range: 3–54 months).Figure 1 Immunohistochemical findings of the degree of expressions
tissue (ANCT). eIF3f was localized in the cytoplasm at different levels and
expression (a) and high expression (b) (magnification × 400). (c) and (d) sh
(d) (magnification × 400).The TNM stage of tumors was assessed according to the
7th ed. of the TNM Classification of GC [21]. The Her-2/
neu overexpression was detected by postoperative fluores-
cence in situ hybridization examination. No patient under-
went radiotherapy or chemotherapy before operation.
For immunohistochemical staining, the paraffin-embedded
tissue sections were obtained from 195 cases of radical
resection of GC. The fragments were fixed in neutral
formol. All the cases were reviewed by a pathologist
to confirm the malignancy. The investigation was ap-
proved by the ethics committee of the medical faculty
and written informed consents were obtained from all
patients.
Immunohistochemistry
The polyclonal antibody (ab64177) to eIF3f was bought
from Abcom (Cambridge, UK). The paraffin-embedded
tissue blocks were sectioned in 3 to 4 mm slices and
placed on Anti slides. After de-waxing and hydration,
the slides were rinsed in phosphate-buffered saline (PBS)
and blocked for 10 min with 3% hydrogen peroxide to
deprive the endogenous peroxidase activity. After anti-
gen retrieval with the use of a microwave, the specimensof eIF3f in gastric cancer (GC) tissue and adjacent non-cancerous
percentages. (a) and (b) show eIF3f staining in GC tissue: low
ow eIF3f staining in ANCT: low expression (c) and high expression
Table 1 Correlation among eIF3f staining and clinical
characteristics






Male 142 49 93 0.87
Female 53 17 36
Age (y)
<60 84 33 51 0.17
≥60 111 33 78
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in PBS) at 37°C for 1.5 hours. The sections were then
washed 3 × 3 min in PBS and incubated with 1 and 2 Re-
agent of PV9000 Mouse/Rabbit hypersensitivity two-step
immunohistochemical Kit (Beijing fir Jinqiao, Beijing,
China) for a total of 60 min at 37°C in a humid chamber.
The sections were washed 3 × 3 min with PBS, followed
by the addition of diaminobenzidine as a chromogen for
3 to 5 min, which was strictly controlled under a micro-
scope. Antibodies were optimized using a positive con-
trol tissue according to the manufacturer’s instructions.
In negative controls, the primary antibody was replaced
with PBS. The remaining procedures were performed in
parallel with other specimens. Each slide was scored in a
blinded fashion by two pathologists according to the
manufacturer’s recommended criteria at × 100 and × 200
magnification. The overall percentage of positive cells on
an immunostained section was determined according to
the pattern of intracellular localization. The extent and
pattern of the eIF3f-specific immunostaining within a
tissue section were determined by the percentage of cells
with cytoplasm staining. The immunostaining was read
in a semiquantitative manner. Three visual fields were
examined randomly and the rate of positive cells was
divided into less than 5% (score 0), 6% to 25% (score 1),
26% to 50% (score 2), 51% to 75% (score 3), and more
than 75% (score 4). The staining intensity can be divided
into three grades: no staining (score 0), slightly yellowish
(score 1), brownish yellow (score 2), and dark brown
(score 3). The multiplication of the two were graded as
follows: 0 (score 0), 1+ (score 1–4), 2+ (score 5–8), and
3+ (score 9–12). Intensity scores of 0 or 1+ were desig-
nated as low expression and 2+ or 3+ were designated
as high expression.Tumor differentiation
Well 12 8 4 0.46
Moderate 27 4 23
Poor 156 54 102
Tumor size (cm)
<4.5 114 34 80 0.16
≥4.5 81 32 49
TNM stage
I–II 136 53 83 0.02
III 59 13 46Statistical analysis
Differences between groups were analyzed using a
Student’s t-test for continuous variables and a χ2 test or
Fisher’s exact test for proportions. The overall survival rate
was estimated by the Kaplan-Meier method. Univariate
analyses (Cox proportional hazard regression models)
were also performed to assess the prognostic value of
nucleolin expression and other clinicopathological fea-
tures. We utilized SAS 9.2 software system for statistical
analysis.Her-2 status
Negative 164 53 111 0.30
Positive 31 13 18
Primary/Recurrent




eIF3f expression and clinicopathological characteristics
From the 195 cases, 142 men and 53 women all accepted
radical operation of GC, including 116 primary and 79
recurrent GC patients. Pathologically, all of the 195 cases
were adenocarcinoma, which covered 12 well differenti-
ated, 27 moderate differentiated, 156 low differentiated,and 4 signet-ring cell carcinoma. For all specimens, 31
cases were demonstrated as Her-2/neu-positive.
eIF3f expression in gastric cancer and ANCT
Immunohistochemical staining for eIF3f showed a cyto-
plasm staining pattern in both GC (Figure 1a, b) and
ANCT (Figure 1c, d) tissues. Immunoscores were calcu-
lated when the presence of eIF3f deposits in tumor
glands and cytoplasmic staining were positive. The rate
of high eIF3f expression in GC and ANCT tissues was
33.8% (66/195) and 59.5% (116/195), respectively.
Correlation between eIF3f expression and
clinicopathological features
The association of eIF3f levels with clinicopathological
features in GC was also assessed in Table 1. Low eIF3f
expression in GC was significantly associated with more
advanced tumor stages (P = 0.02) and likelihood of
recurrence (P = 0.04). However, eIF3f expression was not
significantly correlated with sex (P = 0.87), age (P = 0.17),
tumor differentiation (P = 0.46), and tumor size (P = 0.16).
Out of 136 stage I–II cases, 53 (40.0%) had high eIF3f
Figure 2 Overall survival curves for gastric cancer (GC) patients. (a) Kaplan-Meier overall survival curves for GC patients with tumor size <4.5 cm
and ≥4.5 cm. GC patients with tumor size ≥4.5 cm had significantly shorter overall survival (P = 0.03) than those <4.5 cm. (b) Kaplan-Meier overall
survival curves for primary or recurrent GC patients. Recurrent GC patients had significantly shorter overall survival (P <0.01) than primary GC
patients. (c). A comparison of the overall survival curve between patients with low and high eIF3f expression. The median progression-free
survival was 42.5 months in patients with high eIF3f expression, compared to 33 months in patients with low eIF3f expression.
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Table 2 Univariate and multivariate analysis of overall
survival in patients with gastric cancer






























<4.5 114 2.31 0.04
≥4.5 81 1.04–5.11
Primary/Recurrent
Primary tumor 116 3.77 <0.01
Recurrent tumor 79 1.79–7.94
eIF3f expression
Low 129 2.27 0.04
High 66 1.05–4.92
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cases of stage III (P = 0.02). Furthermore, the overall
densitometric analysis of immunostaining revealed that
the downregulated eIF3f protein expression varied signifi-
cantly between primary and recurrent tumors (P = 0.04).
The relationship between the expression level of eIF3f
and prognosis
The prognostic effect of eIF3f on the survival rate of GC
patients was investigated by comparing the survival rate
of patients with high or low levels of eIF3f protein
expression in tumors using Kaplan-Meier survival curves
and log-rank test. Univariate Cox regression analysis
showed that clinical variables, including tumor size (log-
rank, P = 0.03; Figure 2a), tumor recurrence (log-rank,
P <0.01; Figure 2b), and eIF3f expression (log-rank,
P = 0.04; Figure 2c) were all significantly associated
with overall survival (Table 2). Data indicates that high
expression of eIF3f protein was a significant prognostic
factor for better survival of GC patients. Furthermore,
multivariate Cox regression analyses showed that eIF3f
expression was an independent predictor for the overall
survival of patients with GC.
Discussion
Although the incidence and mortality rate of GC have
fallen over the past several decades, GC is still the fourth
most common cancer and the second leading cause of
cancer-related death in the world [22,23]. Disappointingly,
little improvement has been achieved within the past
several decades despite advances in tumor diagnosis and
treatment [24,25]. Given the high failure rate of conven-
tional treatment strategies, many cancer-related molecules
have been characterized with the goal of developing novel
anticancer strategies.
eIF3f is another eIF3 subunit whose function is not
well-known [18,26]. Previous studies have demonstrated
that overexpression of eIF3f inhibits cell proliferation
and induces apoptosis in melanoma and pancreatic
cancer cells, suggesting that downregulation of eIF3f is
involved in tumorigenesis for many types of cancer
[11,16,19]. However, there is no large sample report
about the expression and clinical significance of eIF3f in
human GC progression and prognosis. In this study, we
investigated the expression of eIF3f in GC as well as its
correlation with the clinicopathological features and
prognosis.
The data from our study showed that the levels of eIF3f
protein were significantly lower in GC tissue compared
with paired ANCT. Additionally, the decreased expression
of eIF3f protein was significantly related to more advanced
tumor stages (P = 0.02) and likelihood of recurrence (P =
0.04). No statistically significant relationship was found
between the eIF3f levels and sex (P = 0.87), age (P = 0.17),tumor differentiation (P = 0.46), and tumor size (P = 0.16).
The Kaplan-Meier survival curves showed that patients
with low eIF3f expression had significantly poorer survival
compared with patients with high eIF3f expression. Fur-
thermore, multivariate Cox regression analyses showed
that tumor size (P = 0.04), recurrence (P <0.01), and eIF3f
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human GC after resection. Based on these results, we
propose a bold hypothesis that a preoperative determin-
ation of eIF3f expression may be useful in predicting the
therapeutic effect and postoperative survival of human
GC. A drawback of the present study is the lack of investi-
gation of eIF3f at the molecular and cellular levels in GC.
Therefore, further studies should be performed for a more
concrete evidence to support the correlation between
eIF3f expression and the malignant degree of GC.
Conclusion
In summary, eIF3f is downregulated in GC. Ultimately,
eIF3f may play an important role in the progression and
recurrence of GC. However, the specific regulatory
mechanisms remain to be further studied to provide
potential targets for the treatment of GC.
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